Emerson has acquired Bioproduction Group (Bio-G), a supplier of simulation, modeling, and scheduling software for biomanufacturing. Bio-G’s scheduling and modeling systems, combined with Emerson’s life sciences technology and expertise portfolio, will help companies bring therapies for cancer, diabetes and other illnesses to patients sooner.
Life sciences companies continually look to accelerate the production of patient therapies and the Bio-G Scheduling software helps them accurately predict future plant resource availability to optimize manufacturing production. The scheduling software delivers a view, accessible across an organization, into the current and future state of the plant, providing decision support to help increase facility uptime and reduce schedule-related product losses.
By connecting analytics and modeling tools with data from automation and operations systems—including Emerson’s DeltaV distributed control system and Syncade manufacturing execution system—the scheduling software provides a unified view of operations, maintenance, quality, and corporate systems. Bio-G’s software will become a part of Emerson’s Plantweb digital ecosystem, an IIoT portfolio that expands digital intelligence to the entire manufacturing enterprise.
Bio-G’s Real-Time Modeling System provides debottlenecking, capacity engineering, and technology transfer analytics to deliver a comprehensive evaluation of a facility’s design and provide confidence prior to project execution and capital expenditure.
The modeling framework identifies and quantifies bottlenecks, as well as determines the effectiveness of proposed solutions across all areas of a manufacturing facility. This modeling system helps accelerate the process of bringing therapies from clinical trials to full-scale manufacturing to patients by validating a facility’s potential for manufacturing success.